Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease

Description

Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for six weeks (12 total visits) and wear the exoskeleton device while walking under the supervision of a trained physical therapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.

Conditions

Parkinson's Disease

Study Overview

Study Details

Study overview

Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for six weeks (12 total visits) and wear the exoskeleton device while walking under the supervision of a trained physical therapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.

Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease

Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease

Condition
Parkinson's Disease
Intervention / Treatment

-

Contacts and Locations

Richmond

Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States, 23249-0001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * PD confirmed by a PADRECC movement disorder specialist using UK Brain Bank Criteria
  • * Modified H\&Y stage II-V
  • * neurological, musculoskeletal, or other disorders unrelated to PD contributing to impairment of stance, gait, balance or coordination
  • * severe CHF, COPD, or those requiring nasal canula O2
  • * history of implantable cardiac device or ablative surgery
  • * moderately-severe to severe cognitive impairment / dementia (Montreal Cognitive Assessment \< 17/30)
  • * symptomatic orthostatic hypotension with exertion
  • * feeding tube or associated port placement (PEG/J-PEG)
  • * body height less than 5'1" or greater than 6'3"
  • * body weight greater than 250 pounds
  • * amputation of any portion of the lower limbs
  • * osteoporosis as defined by DEXA Scan T score \< -2.5
  • * failure to meet B-Temia-established hip and knee flexion and extension manual muscle test (MMT) prerequisite screening parameters, which assure that individuals can adequately engage and walk against the resistive forces of the Keeogo
  • * inability to complete 20 minutes of walking with the exoskeleton (over a maximum period of one hour) at the initial screening/testing session

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

VA Office of Research and Development,

Mark S Baron, MD, PRINCIPAL_INVESTIGATOR, Hunter Holmes McGuire VA Medical Center, Richmond, VA

Study Record Dates

2025-12-31